F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma

被引:76
|
作者
Gallicchio, Rosj [1 ]
Mansueto, Giovanna [1 ]
Simeon, Vittorio [1 ]
Nardelli, Anna [2 ]
Guariglia, Roberto [1 ]
Capacchione, Daniela [1 ]
Soscia, Ernesto [2 ]
Pedicini, Piernicola [1 ]
Gattozzi, Domenico [3 ]
Musto, Pellegrino [1 ]
Storto, Giovanni [1 ]
机构
[1] CROB, IRCCS, I-85028 Rionero In Vulture, Italy
[2] CNR, Ist Biostrutture & Bioimmagini, Naples, Italy
[3] Univ Texas Dallas, Dallas, TX 75230 USA
关键词
survival; quantitative assessment; glycolytic activity; PET/CT; DLBCL; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; INTERNATIONAL PROGNOSTIC INDEX; CHEMOTHERAPY; RITUXIMAB; FLUORODEOXYGLUCOSE; SUBTYPES; IMPACT; SCANS; LINE;
D O I
10.1111/ejh.12268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim We evaluated the prognostic significance of standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) obtained by F-18 FDG PET/CT (PET/CT) in patients with diffuse large B-cell Lymphomas (DLBCL) presenting intermediate IPI score. Material and Methods Fifty-two patients (61 +/- 13yr) underwent PET/CT before the first-line chemotherapy. The mean SUVmax value, the summed MTV (cm(3); 42% threshold), and the cumulative TLG (g) were registered. The patients were followed up 18months thereafter (range 3-41months). The PET/CT results were compared to the event-free survival (EFS). Results At univariate analysis, SUVmax and lactate dehydrogenase (LDH) levels were predictive, but discordantly. The Kaplan-Meier survival analysis for SUVmax showed a significant better EFS in patients presenting higher values as compared to those having lesser (P=0.0002, HR 0.13). Summed MTV and cumulative TLG were not suitable for predicting EFS. Conclusion Despite the availability of new tools for the quantitative assessment of disease activity on PET/CT, the SUVmax rather than MTV and TLG remains the only predictor for EFS in DLBCL patients. The magnitude of glycolytic activity rather than the amount of metabolically active burden holds a predominant value for determining the response to chemotherapy in DLBCL.
引用
收藏
页码:382 / 389
页数:8
相关论文
共 50 条
  • [21] Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma
    Park, Hye Lim
    Han, Eun Ji
    Hyun, Joo
    Choi, Byung-Ock
    Park, Gyeongsin
    Jung, Seung-Eun
    Yahng, Seung-Ah
    Eom, Ki-Seong
    Cho, Seok-Goo
    DIAGNOSTICS, 2020, 10 (12)
  • [22] Prognostic value of interim 18F-FDG PET/CT in diffuse large B-cell lymphoma
    Ying, Zhitao
    Wang, Xuejuan
    Song, Yuqin
    Zheng, Wen
    Wang, Xiaopei
    Xie, Yan
    Lin, Ningjing
    Tu, Meifeng
    Ping, Lingyan
    Liu, Weiping
    Deng, Lijuan
    Zhang, Chen
    Yang, Zhi
    Zhu, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (01) : 95 - 101
  • [23] Prognostic value of interim 18F-FDG PET/CT in diffuse large B-cell lymphoma
    Zhitao Ying
    Xuejuan Wang
    Yuqin Song
    Wen Zheng
    Xiaopei Wang
    Yan Xie
    Ningjing Lin
    Meifeng Tu
    Lingyan Ping
    Weiping Liu
    Lijuan Deng
    Chen Zhang
    Zhi Yang
    Jun Zhu
    Chinese Journal of Cancer Research, 2013, 25 (01) : 95 - 101
  • [24] The Value of 18F-FDG PET/CT in the Prognosis Evaluation of Diffuse Large B-cell Lymphoma
    Li, Yaming
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [25] Bone marrow SUV of pretreatment F-18 FDG PET predicts the clinical outcome in patients with diffuse large B cell lymphoma
    Byun, Byung Hyun
    Kang, Sae-Ryung
    Oh, Jong-Ryool
    Kim, Jahae
    Yoo, Su Woong
    Cho, Sang-Geon
    Chong, Ari
    Min, Jung-Joon
    Bom, Hee-Seung
    Song, Ho-chun
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [26] Application value of 18F-FDG PET/CT metabolic parameters in the prognostic prediction of Diffuse Large B-cell Lymphoma
    Li, J.
    Sun, X.
    Li, Y.
    Yang, J.
    Zhao, Q.
    Yang, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S558 - S558
  • [27] 18f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients
    Eertink, Jakoba J.
    van de Brug, Tim
    Wiegers, Sanne E.
    Zwezerijnen, Gerben J. C.
    Pfaehler, Elisabeth
    Lugtenburg, Pieternella J.
    van der Holt, Bronno
    de Vet, Henrica C. W.
    Hoekstra, Otto S.
    Boellaard, Ronald
    Zijlstra, Josee M.
    BLOOD, 2020, 136
  • [28] Baseline and interim 18F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma
    Liao, Chengcheng
    Deng, Qifeng
    Zeng, Lin
    Guo, Baoping
    Li, Zhe
    Zhou, Da
    Ke, Qing
    Wang, Mingyue
    Huang, Mei
    Tan, Xiaohong
    Cen, Hong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [29] Predictive value of F-18 FDG PET/CT quantification parameters for progression-free survival in patients with B-cell lymphoma
    He, W.
    Zhai, W.
    Yu, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S693 - S693
  • [30] The Central Cavitation in Pulmonary Diffuse Large B-Cell Lymphoma Detected by 18F-FDG PET/CT
    Lin, Nan
    Xie, Hangyu
    Zhang, Wenjie
    Ma, Xuelei
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (06) : 562 - 563